TY  - CHAP
M1  - Book, Section
TI  - Waldenström Macroglobulinemia
A1  - Becnel, Melody
A1  - Kaufman, Gregory P.
A1  - Manasanch, Elisabet E.
A1  - Patel, Krina
A1  - Lee, Hans C.
A1  - Orlowski, Robert Z.
A1  - Thomas, Sheeba
A2  - Kantarjian, Hagop M.
A2  - Wolff, Robert A.
A2  - Rieber, Alyssa G.
Y1  - 2022
N1  - 
T2  - The MD Anderson Manual of Medical Oncology, 4e
AB  - KEY  CONCEPTSWaldenström  macroglobulinemia  (WM)  is  synonymous  with  lymphoplasmacytic  lymphoma  as  well  as  the  presence  of  a  monoclonal  immunoglobulin  (Ig)  M  gammopathy.Most  cases  are  associated  with  a  mutation  in  MYD88,  which  offers  a  better  prognosis  than  MYD88  wild-type  cases.CXCR4  mutations  are  associated  with  increased  IgM  levels  and  a  higher  risk  of  hyperviscosity.Patients  with  WM  are  at  risk  for  symptomatic  hyperviscosity  syndrome,  which  may  present  with  visual  disturbances,  dizziness,  cardiopulmonary  symptoms,  decreased  consciousness,  and  a  bleeding  diathesis.  Therapy  for  hyperviscosity  consists  of  prompt  initiation  of  plasma  exchange  followed  by  systemic  therapy.As  with  other  low-grade  lymphoid  malignancies,  asymptomatic  patients  and  those  without  significant  cytopenias  or  other  end-organ  manifestations  can  be  observed  with  close  follow-up.Therapy  should  be  initiated  for  symptomatic  hyperviscosity,  hemoglobin  less  than  10  g/dL,  platelet  count  100,000  K/uL  or  less,  bulky  adenopathy,  symptomatic  organomegaly,  symptomatic  cryoglobulinemia,  or  significant  peripheral  neuropathy  
SN  - 
PB  - McGraw Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1190833558
ER  -